ArticleJCPP advances2026
Prenatal exposure to antihypertensive medication: A systematic review of neurodevelopmental and educational outcomes.
Article in JCPP advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Where possible, medication is avoided during pregnancy as it can cross the placenta and potentially cause congenital malformations, impair growth and have longer-term functional or cognitive sequelae. However, medication is sometimes required for pre-existing or new-onset conditions such as hypertension disorders during pregnancy; the longer-term outcomes of which remain unclear. This systematic review aimed to synthesise the evidence on prenatal exposure to antihypertensive medication and longer-term neurodevelopmental and educational outcomes up to 18 years of age. Methods: We searched Medline Ovid, PubMed, Excerpta Medica Database, and Web of Science from inception (1946) until 04 July 2025, selecting observational and experimental studies. The inclusion criteria for eligible studies were pregnant women with or without any hypertension disorder of pregnancy, mothers taking antihypertensive medication during pregnancy comparing them with those not exposed, children ≥1 years of age, and children with one of the predefined neurodevelopmental and educational outcomes. The studies' quality was evaluated using the National Heart, Lung, and Blood Institute assessment tool. Results: Of 11 studies included (five cohorts, two case-control and four randomised controlled trials), 10 were of high quality, while only one was of low quality. Six of the 11 studies demonstrated significant associations between prenatal exposure to antihypertensive medication and at least one adverse neurodevelopmental outcome in children. One study reported an increased risk of autism spectrum disorder following calcium channel blockers and beta-blockers exposure, one reported the risk of fine motor problems following calcium channel blockers exposure, one reported increased risk of low intelligence quotient following exposure to methyldopa, one reported an increased risk of attention deficit hyperactivity disorder following exposure to beta-blockers, one reported speech problems following exposure to more than one antihypertensive medications, and one reported an increased risk of sleeping disturbance following exposure to clonidine. Methodological heterogeneity, small sample sizes, and inadequate confounder adjustment were common limitations. Conclusions: The association between prenatal antihypertensive exposure and neurodevelopmental outcomes warrants further research, focusing on the impacts of specific medication classes on a range of outcomes in the same study population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.